The global point-of-care diagnostics market is projected to grow from USD 20.63 billion in 2026 to USD 31.46 billion by 2031, representing a compound annual growth rate of 8.8% from 2026 to 2031, MarketsandMarkets™ said. Point-of-care diagnostics (testing near the patient) are benefiting from the rising prevalence of chronic and infectious diseases, demand for rapid and accurate results, aging populations, higher healthcare utilization, portable technology advances, home-based testing and digital connectivity. Glucose monitoring products are the largest product segment, while hospitals, critical care centers and urgent care centers are the largest end-user segment. Home care settings and self-testing are growing fastest, and Asia Pacific represents the largest regional growth opportunity. The market includes glucose, infectious disease, cardiac biomarker, blood gas and electrolyte, coagulation, HbA1c, urinalysis, pregnancy and fertility, molecular diagnostic and multiplex respiratory testing. Growth is also supported by telehealth, connected diagnostic systems, smartphone-enabled devices and AI-assisted interpretation, although stringent and differing regulatory requirements raise development costs and can delay launches. Leading companies include Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, QuidelOrtho Corporation, Danaher, Becton, Dickinson, and Company, Thermo Fisher Scientific, Inc., bioMérieux, EKF Diagnostics, QIAGEN, Werfen S.A, OraSure Technologies, Trinity Biotech, Grifols S.A, Nova Biomedical, Sekisui Diagnostics, Trividia Health, Sysmex Corporation, HemoCue, Bio-Rad Laboratories, Chembio Diagnostics, Johnson & Johnson, LifeScan, Ascensia Diabetes Care, ARKRAY, Sinocare and Wondfo Biotech.